# Alteration of erythrocyte membrane polyunsaturated fatty acids in preterm newborns with retinopathy of prematurity

Charlotte Pallot, Julie Mazzocco, Cyril Meillon, Denis S. Semama, Corinne Chantegret, Ninon Ternoy, Delphine Martin, Aurélie Donier, Stéphane Grégoire, Catherine P. Creuzot Garcher, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

Charlotte Pallot, Julie Mazzocco, Cyril Meillon, Denis S. Semama, Corinne Chantegret, et al. Alteration of erythrocyte membrane polyunsaturated fatty acids in preterm newborns with retinopathy of prematurity. Scientific Reports, 2019, 9 (1), pp.7930. 10.1038/s41598-019-44476-w. hal-02621983

HAL Id: hal-02621983

https://hal.inrae.fr/hal-02621983

Submitted on 26 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
SCIENTIFIC REPORTS

OPEN

# Alteration of erythrocyte membrane polyunsaturated fatty acids in preterm newborns with retinopathy of prematurity

Charlotte Pallot<fnref n="1" />, Julie Mazzocco², Cyril Meillon<fnref n="1" />, Denis S. Semama³, Corinne Chantegret³, Ninon Ternoy³, Delphine Martin³, Aurélie Donier³, Stéphane Gregoire², Catherine P. Creuzot-Garcher<fnref n="1" />,², Alain M. Bron ID <fnref n="1" />,², Lionel Bretillon² & Niyazi Acar²

Received: 1 October 2018

Accepted: 17 May 2019

Published online: 28 May 2019

Extremely preterm infants are at high risk for retinopathy of prematurity (ROP), a potentially blinding disease characterized by abnormalities in retinal vascularization. Whereas animal studies revealed that n-3 polyunsaturated fatty acids (PUFAs) may be of benefit in preventing ROP, human studies conducted on preterm infants during the 1st weeks of life showed no association between blood n-3 PUFA bioavailability and ROP incidence and/or severity, probably because of the influence of nutrition on the lipid status of infants. In the OmegaROP prospective cohort study, we characterized the erythrocyte concentrations of PUFAs in preterm infants aged less than 29 weeks gestational age (GA) without any nutritional influence. We show that GA is positively associated with the erythrocyte n-6 to n-3 PUFA ratio, and particularly with the ratio of arachidonic acid (AA) to docosahexaenoic acid (DHA), in infants with ROP. A time-dependent accumulation of AA at the expense of DHA seems to occur in utero in erythrocytes of preterm infants who will develop ROP, thus reinforcing previous data on the beneficial properties of DHA on this disease. In addition, preliminary data on maternal erythrocyte membrane lipid concentrations suggest modifications in placental transfer of fatty acids. Documenting the erythrocyte AA to DHA ratio at birth in larger cohorts might be useful to set up new prognostic factors for ROP.

The incomplete vascularization of the retina in preterm infants carries a risk of developing retinopathy of prematurity (ROP). ROP is characterized by neovascular complications that are the consequence of an imbalanced oxygen supply to the retina. ROP was first described in 1942 by Terry, who termed it "retrolental fibroplasia", referring to the total retinal detachment observed in the most severe stages of ROP<fnref n="1" />.

Retinal vascularization begins in utero by the development of the embryonic vasculature that fully regresses before birth. Then an own vascular network develops through two complementary mechanisms, vasculogenesis and angiogenesis. Vasculogenesis begins at 6 weeks of embryonic life by the formation of four vascular arcades. Angiogenesis then takes place until the first 2 weeks after birth and corresponds to the emergence of vessels from these arcades. This late maturation makes infants born before the end of the third quarter of pregnancy at high risk of ROP. Although better knowledge of risk factors and improved screening and treatment have significantly decreased the risk of developing ROP, this disease remains the major cause of blindness in preterm infants². The incidence of ROP in developed countries is highly variable and ranges from 6 to 34%³,⁴. Preterm birth (commonly before 32 weeks of gestational age (GA))⁵ and lower birth weight (usually below 1500 g)⁶ are independent risk factors of ROP, whereas high oxygen saturation is the major cause for developing the disease⁷. Other risk factors such as red blood cell transfusion⁸, use of erythropoietin (EPO)⁹, hyperglycemia¹⁰, and maternal anemia¹¹ have also been identified.

Polyunsaturated fatty acids (PUFAs) from n-3 series have been shown to reduce by more than 50% the incidence of early preterm birth¹²,¹³. They also appear to be strong regulators of perinatal retinal vascular

<footnote n="1">¹University Hospital, Department of Ophthalmology, Dijon, F-21000, France. ²Centre des Sciences du Goût et de l'Alimentation, AgroSup Dijon, CNRS, INRA, Université Bourgogne Franche-Comté, Eye and Nutrition Research Group, Dijon, F-21000, France. ³University Hospital, Neonatal Intensive Care Unit, Dijon, F-21000, France. Correspondence and requests for materials should be addressed to N.A. (email: niyazi.acar@inra.fr)</footnote>
<table><caption>**Table 1.** Main characteristics of the population. Continuous variables are expressed as median [IQR], categorical variables are expressed as No. (%). ROP: retinopathy of prematurity; RBC: red blood cells. *p*-values in bold indicate a statistically significant difference (*p* < 0.05).</caption><thead><tr><th></th><th>Total population<br>n = 52</th><th>ROP<br>n = 27</th><th>No-ROP<br>n = 25</th><th>P-value</th></tr></thead><tbody><tr><td>Sampling time (h)</td><td>12 [12–24]</td><td>12 [12–21]</td><td>12 [12–30]</td><td>0.0569</td></tr><tr><td>Male</td><td>26 (50.0)</td><td>14 (51.8)</td><td>12 (48.0)</td><td>0.7813</td></tr><tr><td>Gestational age (weeks)</td><td>27.1 [26.2–27.7]</td><td>26.5 [25.5–27.1]</td><td>27.6 [27.1–28.4]</td><td><strong>0.0009</strong></td></tr><tr><td>Birth weight (g)</td><td>887 [797–1081]</td><td>815 [735–967]</td><td>1020 [870–1160]</td><td><strong>0.0014</strong></td></tr><tr><td>ROP</td><td>27 (51.9)</td><td>27 (100)</td><td>—</td><td>—</td></tr><tr><td>ROP treated</td><td>3 (5.8)</td><td>3 (11.1)</td><td>—</td><td>—</td></tr><tr><td>ROP detection (weeks)</td><td>8.2 [6.6–9.5]</td><td>8.2 [6.6–9.5]</td><td>—</td><td>—</td></tr><tr><td>Mechanical ventilation (days)</td><td>7.0 [1.0–14.0]</td><td>11.0 [5.5–16.5]</td><td>2.0 [1.0–7.0]</td><td><strong>0.0004</strong></td></tr><tr><td>Sepsis</td><td>23 (44.2)</td><td>16 (59.2)</td><td>7 (28.0)</td><td><strong>0.0233</strong></td></tr><tr><td>Erythropoietin use</td><td>33 (63.4)</td><td>18 (66.6)</td><td>15 (60.0)</td><td>0.6179</td></tr><tr><td>RBC transfusion</td><td>25 (48.0)</td><td>17(62.9)</td><td>8(32.0)</td><td><strong>0.0255</strong></td></tr><tr><td>Cerebral hemorrhage</td><td>25 (48.0)</td><td>13 (48.1)</td><td>12 (48.0)</td><td>0.9914</td></tr></tbody></table>

development. Indeed, n-3 PUFAs have been shown to prevent the vascular architecture defects observed in a mouse model of oxygen-induced retinopathy, an animal model of ROP<sup>14–17</sup>. Particularly, n-3 PUFAs modulate cellular pathways activated by IGF-1<sup>18</sup> and endothelial cellular proliferation through VEGF signaling<sup>19,20</sup>, with IGF-1 and VEGF the cellular pathways implicated in the pathogenesis of ROP<sup>21–24</sup>. To our knowledge, few data is available on the lipid or PUFA status in preterm infants developing ROP. Martin *et al.* evaluated the postnatal evolution of the whole blood PUFA concentration in preterm newborns and showed strong modifications in the levels of the major n-6 and n-3 PUFAs arachidonic acid (AA) and docosahexaenoic acid (DHA), but without finding any association with the ROP phenotype<sup>25</sup>. In a longitudinal study, Löfqvist *et al.* showed that a lower area under the curve of serum AA during the 1st month of life is associated with a later diagnosis of ROP<sup>26</sup>. However, in these studies lipids were measured, at least in part, after enteral and parenteral feeding, and might then have been influenced by the oral or intravenous lipid supplements.

In the OmegaROP study, we wished to evaluate the prospective value of erythrocyte concentrations of n-3 and n-6 PUFAs for the development of ROP in preterm infants. We measured the individual concentrations of n-3 and n-6 PUFAs in red blood cells collected immediately after birth, in order to limit the interference with lipid nutritional intakes, and recorded the incidence of ROP.

## Results

**Characteristics of the population.** The characteristics of the population are presented in Table 1. Fifty-eight preterm infants born before 29 weeks GA were included. Six infants died and the mortality rate was 11.5%. Blood samples were obtained from 52 infants at a median time of 12 h and a maximum time of 48 h after birth. The population included five sets of heterozygote twins. No difference was observed between the ROP and the no-ROP groups for sampling time, gender, use of EPO and cerebral hemorrhage. ROP was associated with significantly higher sepsis and red blood cell transfusion (*p* = 0.0233 and *p* = 0.0255, respectively), lower GA and birth weight (*p* = 0.0009 and *p* = 0.0014, respectively) and higher duration of mechanical ventilation (*p* = 0.0004). The mean follow-up for ROP screening was 11.3 ± 4.5 weeks of life. The mean number of screening examinations was 3.6 ± 2.0 per infant. The incidence of ROP was 51.9% with three cases with type 1 ROP (11.1%) and 24 type 2 ROP cases (88.9%). Type 1 ROP subjects underwent laser therapy in both eyes. No intravitreal injection of bevacizumab was used. Twenty-six ROP cases (96.3%) were observed in zone 2 and one ROP case (3.7%) was observed in zone 3. No ROP in zone 1 was observed. There was one case of ROP at stage 1 (3.7%), 19 cases at stage 2 (70.4%) and seven cases at stage 3 (25.9%). Four subjects were classified as a stage “plus” and three of them underwent laser treatment.

**Fatty acid composition of erythrocytes.** No significant difference was observed between groups in individual fatty acids as well as in total saturated fatty acid (SFA), total monounsaturated fatty acid (MUFA), total PUFA, and total dimethylacetals (DMA) (Table 2). The levels of total n-3 PUFAs, n-6 PUFAs and the total n-6 to total n-3 PUFA ratio were similar between the groups (*p* = 0.9513, *p* = 0.9120 and *p* = 0.8538, respectively). A striking characteristic of the measured erythrocyte fatty acid compositions of subjects from the ROP and no-ROP groups was high variability, especially in the levels of total SFA, total MUFA, total PUFA, total n-6 PUFA and total n-3 PUFA (Fig. 1).

**Principal component analysis of erythrocyte fatty acid composition.** To better understand the origin of the data dispersion, we carried out a principal component analysis of the lipidomic data in relation to the major risk factors of ROP, namely mechanical ventilation, birthweight and GA (Fig. 2). The F1- and F2-axes explained 53.30% and 21.07% of data variance in the no-ROP group and 51.00% and 19.81% in the ROP group, respectively. In the no-ROP group, data variance on the F1-axis was almost exclusively the reflection of the variability in fatty acid composition (85.51% contribution to the F1-axis), whereas the risk factors for ROP were the
<table><caption>**Table 2.** Erythrocyte fatty acid composition of preterm infants without or with retinopathy of prematurity. Results are expressed as % of total fatty acid methyl esters (FAMES) + dimethylacetals (DMAs). ROP: retinopathy of prematurity; IQR: inter quartile range; DMA: dimethylacetals; LA: linoleic acid, ALA; α-linolenic acid; AA: arachidonic acid; EPA: eicosapentaenoic acid; n-6 DPA: n-6 docosapentaenoic acid; n-3 DPA: n-3 docosapentaenoic acid; DHA: docosahexaenoic acid; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids.</caption><thead><tr><th rowspan="2"></th><th colspan="2">No-ROP n = 25</th><th colspan="2">ROP n = 27</th><th rowspan="2">p Value</th></tr><tr><th>Median</th><th>IQR</th><th>Median</th><th>IQR</th></tr></thead><tbody><tr><td>C14:0</td><td>0.19</td><td>[0.10–0.23]</td><td>0.15</td><td>[0.09–0.20]</td><td>0.1631</td></tr><tr><td>C15:0</td><td>0.13</td><td>[0.10–0.24]</td><td>0.11</td><td>[0.10–0.18]</td><td>0.4062</td></tr><tr><td>DMA16:0</td><td>1.88</td><td>[1.49–2.31]</td><td>1.80</td><td>[1.54–2.08]</td><td>0.2302</td></tr><tr><td>C16:0</td><td>22.88</td><td>[20.76–33.63]</td><td>23.37</td><td>[21.29–30.04]</td><td>0.9581</td></tr><tr><td>C16:1n-9</td><td>0.27</td><td>[0.21–0.33]</td><td>0.23</td><td>[0.19–0.28]</td><td>0.4515</td></tr><tr><td>C16:1n-7</td><td>0.51</td><td>[0.37–0.56]</td><td>0.40</td><td>[0.23–0.51]</td><td>0.3892</td></tr><tr><td>C17:0</td><td>0.28</td><td>[0.24–0.64]</td><td>0.33</td><td>[0.25–0.72]</td><td>0.8881</td></tr><tr><td>DMA18:0</td><td>4.50</td><td>[4.08–4.87]</td><td>4.29</td><td>[3.91–4.77]</td><td>0.8615</td></tr><tr><td>DMA18:1n-9</td><td>0.82</td><td>[0.49–0.95]</td><td>0.93</td><td>[0.47–1.12]</td><td>0.4979</td></tr><tr><td>DMA18:1n-7</td><td>0.25</td><td>[0.19–0.36]</td><td>0.32</td><td>[0.18–0.40]</td><td>0.7582</td></tr><tr><td>C18:0</td><td>16.55</td><td>[14.63–28.33]</td><td>15.33</td><td>[14.82–30.25]</td><td>0.9437</td></tr><tr><td>C18:1t</td><td>0.15</td><td>[0.08–0.19]</td><td>0.17</td><td>[0.10–0.21]</td><td>0.8603</td></tr><tr><td>C18:1n-9</td><td>10.85</td><td>[7.99–12.84]</td><td>11.65</td><td>[6.36–12.96]</td><td>0.8250</td></tr><tr><td>C18:1n-7</td><td>2.38</td><td>[1.41–2.71]</td><td>2.45</td><td>[0.98–2.69]</td><td>0.8752</td></tr><tr><td>C18:2n-6 (LA)</td><td>3.24</td><td>[2.57–3.59]</td><td>3.04</td><td>[1.94–3.54]</td><td>0.8380</td></tr><tr><td>C20:0</td><td>0.29</td><td>[0.25–0.36]</td><td>0.29</td><td>[0.25–0.37]</td><td>0.4936</td></tr><tr><td>C20:1n-9</td><td>0.20</td><td>[0.17–0.22]</td><td>0.19</td><td>[0.16–0.25]</td><td>0.9558</td></tr><tr><td>C18:3n-3 (ALA)</td><td>0.06</td><td>[0.05–0.09]</td><td>0.08</td><td>[0.07–0.11]</td><td>0.4494</td></tr><tr><td>C20:2n-6</td><td>0.14</td><td>[0.12–0.16]</td><td>0.14</td><td>[0.14–0.16]</td><td>0.5954</td></tr><tr><td>C20:3n-9</td><td>0.57</td><td>[0.39–0.75]</td><td>0.48</td><td>[0.25–0.67]</td><td>0.4961</td></tr><tr><td>C22:0</td><td>0.52</td><td>[0.47–0.70]</td><td>0.46</td><td>[0.44–0.73]</td><td>0.9256</td></tr><tr><td>C20:3n-6</td><td>2.03</td><td>[1.58–2.59]</td><td>1.87</td><td>[1.44–2.22]</td><td>0.3053</td></tr><tr><td>C20:4n-6 (AA)</td><td>17.19</td><td>[7.98–18.96]</td><td>18.06</td><td>[8.78–19.54]</td><td>0.8558</td></tr><tr><td>C20:5n-3 (EPA)</td><td>0.54</td><td>[0.40–0.67]</td><td>0.52</td><td>[0.37–0.63]</td><td>0.4957</td></tr><tr><td>C24:0</td><td>1.51</td><td>[1.18–2.16]</td><td>1.23</td><td>[1.14–2.12]</td><td>0.9512</td></tr><tr><td>C24:1n-9</td><td>1.09</td><td>[0.96–1.35]</td><td>1.17</td><td>[0.98–1.34]</td><td>0.7550</td></tr><tr><td>C22:4n-6</td><td>2.26</td><td>[1.48–2.65]</td><td>2.45</td><td>[1.61–2.60]</td><td>0.7424</td></tr><tr><td>C22:5n-6 (n-6 DPA)</td><td>0.91</td><td>[0.43–0.98]</td><td>0.85</td><td>[0.55–1.12]</td><td>0.9322</td></tr><tr><td>C22:5n-3 (n-3 DPA)</td><td>0.37</td><td>[0.23–0.52]</td><td>0.45</td><td>[0.24–0.55]</td><td>0.4546</td></tr><tr><td>C22:6n-3 (DHA)</td><td>4.08</td><td>[1.71–4.86]</td><td>3.74</td><td>[2.11–4.96]</td><td>0.9276</td></tr><tr><td>Total SFA</td><td>39.68</td><td>[37.95–62.13]</td><td>41.08</td><td>[38.65–66.59]</td><td>0.9580</td></tr><tr><td>Total MUFA</td><td>15.08</td><td>[11.76–18.08]</td><td>16.31</td><td>[9.24–17.99]</td><td>0.8302</td></tr><tr><td>Total PUFA</td><td>33.20</td><td>[17.03–35.61]</td><td>34.86</td><td>[17.63–35.54]</td><td>0.9499</td></tr><tr><td>Total DMA</td><td>7.52</td><td>[6.71–8.07]</td><td>7.28</td><td>[6.71–8.06]</td><td>0.7101</td></tr><tr><td>Total n-3</td><td>5.16</td><td>[2.38–6.11]</td><td>5.16</td><td>[2.78–6.24]</td><td>0.9513</td></tr><tr><td>Total n-6</td><td>26.43</td><td>[14.19–29.06]</td><td>27.73</td><td>[14.58–28.88]</td><td>0.9120</td></tr><tr><td>n-6/n-3</td><td>4.85</td><td>[3.99–5.47]</td><td>4.91</td><td>[4.33–5.38]</td><td>0.8538</td></tr></tbody></table>

major contributors of the F2-axis (83.75% contribution). In the no-ROP group, principal component analysis indicated that total MUFA, total PUFA, total n-6 PUFA and total n-3 PUFA formed a group loaded high on F1, whereas total SFA, birthweight and GA were very highly negative. The major difference in the ROP group when compared to the no-ROP group concerned the total n-6 to n-3 PUFA ratio, which switched from the center to a positive position on the F2-axis. This change resulted in the formation of a new cluster highly loaded on the F2-axis and composed of GA and the n-6 PUFA to n-3 PUFA ratio, suggesting a close interaction between these two variables in the ROP group.

**Associations between gestational age and erythrocyte lipids.** Considering the results from principal component analysis, we checked for Spearman correlations between GA and total SFA, total MUFA, total PUFA, total n-6 PUFA, total n-3 PUFA and the n-6 PUFA to n-3 PUFA ratio (Fig. 3A). In the no-ROP group, GA was positively associated with erythrocyte total SFA concentrations (rSpearman = 0.441, p = 0.0273) and negatively associated with erythrocyte total MUFA, total PUFA and total n-3 PUFA (rSpearman = -0.441, -0.419 and
<figure><img src="image_3.png" /><figcaption>**Figure 1.** Distribution of the total n-6 to total n-3 PUFA ratio, total n-3 PUFA, total n-6 PUFA, total DMA, total MUFA, total PUFA and total SFA in the ROP and no-ROP groups. Results are presented as median, first and third quartiles, and range. ROP: retinopathy of prematurity; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; FAMEs: fatty acid methyl esters; DMAs: dimethylacetals.</figcaption></figure>

<figure><img src="image_4.png" /><figcaption>**Figure 2.** Principal component analysis of erythrocyte fatty acids and major risk factors of ROP in subjects with or without ROP. ROP: retinopathy of prematurity; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids.</figcaption></figure>

−0.430, respectively; *p* = 0.0270, 0.0368 and 0.0317, respectively). In the ROP group, only GA and the n-6 to n-3 ratio showed a significant positive association (*r* Spearman = 0.570, *p* = 0.0019).

We further investigated at which level of n-6 and n-3 PUFA metabolism the n-6 to n-3 ratio association with GA is discordant between the no-ROP and ROP groups. Long-chain PUFAs from the n-6 and n-3 series such as n-6 docosapentaenoic acid (n-6 DPA) and DHA are synthesized from linoleic acid (LA) and α-linolenic acid (ALA), respectively, through metabolic reactions involving desaturation by Fatty Acid Desaturase 2 (FADS2), elongation by ELOngation of Very Long-chain fatty acid 5,2 (ELOVL5,2) and Fatty Acid Desaturase 1 (FADS1) to synthesize AA and eicosapentaenoic acid (EPA), respectively, which are elongated by ELOVL5,2 to C22:4n-6 and n-3 docosapentaenoic acid (n-3 DPA), which in turn are elongated by ELOVL2, desaturated by FADS2 and finally β-oxidized (Fig. 3B). Although no association was found between individual n-6 PUFAs and GA in the no-ROP and ROP groups, strong negative associations were found between EPA and GA in the no-ROP group (*r* Spearman = −0.582, *p* = 0.0022) and ALA and GA in the ROP group (*r* Spearman = −0.457, *p* = 0.0163) (Table 3 and Fig. 3C). Within the different steps of n-6 and n-3 PUFA metabolism, only the ratio of most desaturated 22-carbon PUFAs, namely n-6 DPA and DHA, was positively associated with GA in the no-ROP group (*r* Spearman = 0.422, *p* = 0.0356). Interestingly, the ratio of the most prevalent PUFAs in the retina, AA and DHA, displayed a very strong positive association with GA in the ROP group only (*r* Spearman = 0.595, *p* = 0.0010) (Fig. 3C).
A.

<figure><img src="image_5.png" /></figure>

<figure><img src="image_6.png" /></figure>

B.

<figure><img src="image_7.png" /></figure>

C.

<figure><img src="image_8.png" /></figure>

<figure><img src="image_9.png" /></figure>

**Figure 3.** Origin of the differential evolution of the erythrocyte lipid composition according to gestational age in subjects with or without ROP. (A) Association between gestational age and total SFA, total MUFA, total PUFA, total n-6 PUFA, total n-3 PUFA and the total n-6 PUFA to total n-3 PUFA ratio in preterm infants with or without ROP. (B) Sequence of metabolic reactions leading to n-3 and n-6 long-chain PUFA synthesis. DHA and n-6 DPA are synthesized from ALA and LA, respectively, through metabolic reactions involving FADS2, ELOVL5,2, FADS1 and β-oxidation. (C) Association between gestational age and EPA, and the AA to DHA ratio in preterm infants with or without ROP. ROP: retinopathy of prematurity; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; FADS2: Fatty Acid Desaturase 2; ELOVL5,2: ELOngation of Very Long-chain fatty acid 5,2; FADS1: Fatty Acid Desaturase 1; LA: linoleic acid, AA: arachidonic acid; DPA: docosapentaenoic acid; ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; NS: non significant; FAMES: fatty acid methyl esters; DMAs: dimethylacetals.

**Fatty acid composition of mother's erythrocytes.** Eight mothers were included in the study. Within them, 3 gave birth to preterm infants that developed ROP. The fatty acid analyses showed a significant reduction in erythrocyte levels of C22:4n-6 (*p* = 0.0179) balanced by a significant increase of DHA concentrations (*p* = 0.0357) of mothers of preterm infants that will develop ROP (Fig. 4). Whereas the n-6 PUFA to n-3 PUFA ratio was unchanged, mothers of children with ROP displayed a significantly reduced AA to DHA ratio in erythrocyte membranes (*p* = 0.0357).

**Discussion**

This report characterizes the erythrocyte concentrations of fatty acids in preterm infants born before 29 weeks GA. The clinical characteristics of our population were comparable with those of several studies. The main risk factors for ROP in the present study were early GA, low birth weight and mechanical ventilation, as reported by others<sup>11,27,28</sup>. The incidence of ROP in our study was high (51.9%) and in agreement with other very-low-GA populations<sup>29</sup>.
<table><caption>**Table 3.** Spearman correlations between gestational age and erythrocyte n-6 and n-3 polyunsaturated fatty acids of preterm infants with or without retinopathy of prematurity. ROP: retinopathy of prematurity; PUFA: polyunsaturated fatty acids; LA: linoleic acid, ALA; α-linolenic acid; n-6 DPA: AA: arachidonic acid; EPA: eicosapentaenoic acid; n-6 DPA: n-6 docosapentaenoic acid; n-3 DPA: n-3 docosapentaenoic acid; DHA: docosahexaenoic acid.</caption><thead><tr><th rowspan="2"></th><th colspan="2">No-ROP<br>n = 25</th><th colspan="2">ROP<br>n = 27</th></tr><tr><th>rSpearman</th><th>P-value</th><th>rSpearman</th><th>P-value</th></tr></thead><tbody><tr><td colspan="5"><strong>n-6 PUFAs</strong></td></tr><tr><td>C18:2n-6 (linoleic acid, LA)</td><td>-0.354</td><td>0.0817</td><td>0.230</td><td>0.2467</td></tr><tr><td>C20:4n-6 (arachidonic acid, AA)</td><td>-0.300</td><td>0.1447</td><td>-0.012</td><td>0.9511</td></tr><tr><td>C22:4n-6</td><td>-0.315</td><td>0.1251</td><td>0.026</td><td>0.8958</td></tr><tr><td>C22:5n-6 (n-6 docosapentaenoic acid, n-6 DPA)</td><td>-0.321</td><td>0.1169</td><td>-0.1233</td><td>0.5402</td></tr><tr><td colspan="5"><strong>n-3 PUFAs</strong></td></tr><tr><td>C18:3n-3 (α-linolenic acid, ALA)</td><td>0.061</td><td>0.7693</td><td><strong>-0.457</strong></td><td><strong>0.0163</strong></td></tr><tr><td>C20:5n-3 (eicosapentaenoic acid, EPA)</td><td><strong>-0.582</strong></td><td><strong>0.0022</strong></td><td>0.062</td><td>0.7577</td></tr><tr><td>C22:5n-3 (n-3 docosapentaenoic acid, n-3 DPA)</td><td>-0.367</td><td>0.0712</td><td>0.009</td><td>0.9607</td></tr><tr><td>C22:6n-3 (docosahexaenoic acid, DHA)</td><td>-0.396</td><td>0.0500</td><td>-0.176</td><td>0.3774</td></tr><tr><td colspan="5"><strong>ratios</strong></td></tr><tr><td>C18:2n-6/C18:3n-3 (LA/ALA)</td><td>-0.216</td><td>0.2978</td><td>0.3414</td><td>0.0813</td></tr><tr><td>C20:4n-6/C20:5n-3 (AA/EPA)</td><td>-0.202</td><td>0.3307</td><td>0.090</td><td>0.6540</td></tr><tr><td>C22:4n-6/C22:5n-3 (C22:4n-6/n-3 DPA)</td><td>-0.061</td><td>0.7710</td><td>0.251</td><td>0.2065</td></tr><tr><td>C22:5n-6/C22:6n-3 (n-6 DPA/DHA)</td><td><strong>0.422</strong></td><td><strong>0.0356</strong></td><td>-0.055</td><td>0.7837</td></tr><tr><td>C20:4n-6/C22:6n-3 (AA/DHA)</td><td>-0.188</td><td>0.3668</td><td><strong>0.595</strong></td><td><strong>0.0010</strong></td></tr></tbody></table>

Whereas Martin *et al.* and Löfqvist *et al.* looked at whole blood and plasma lipids, respectively<sup>25,26</sup>, the present study is to our knowledge the first characterizing erythrocyte lipids in preterm infants born before 29 weeks GA. The data show that the erythrocyte fatty acid profile in preterm infants born before 29 weeks GA resembles that measured in older subjects<sup>30</sup>. However, inter-individual variability was very high in our population. This might reflect the particular status of preterm infants and may suggest strong remodeling of fatty acid metabolism during gestation. This variability was not restricted to any specific fatty acid but seemed to concern all of them. The novelty of this study is that blood was sampled early in life in order to avoid any modification of the erythrocyte lipid status by the diet. Considering the erythrocyte lifetime ranging from 35 to 50 days in preterm infants<sup>31</sup>, and a blood sampling achieved within the first 48 h of life, the probability that the fatty acid compositions presented here are affected by the diet is null. Therefore, the variations observed in the present study might be assigned to differences in *in situ* fatty acid metabolisms rather than to a nutritional influence. In the studies reported by Collins *et al.* and Smither *et al.*, the concentrations of total n-3 PUFAs were higher, but blood was sampled after 28 days of life<sup>32,33</sup>. Higher n-3 PUFA concentrations are therefore probably the consequence of the dietary supply during early life.

It is now well established that n-3 PUFAs play crucial roles in retinal angiogenesis and vascularization<sup>14,34</sup>. Whereas n-6 PUFAs display opposite properties, it was demonstrated that n-3 PUFAs limit the severity of pathologic retinal neovascularization and improve the regression of vascular lesions<sup>14,16,34,35</sup>. Epidemiologic studies have shown that a higher dietary consumption of n-3 PUFAs is associated with a decreased risk of neovascular forms of age-related macular degeneration (AMD)<sup>36,37</sup>, vascular abnormalities in diabetic retinopathy<sup>38</sup> and vascular architecture defects in a mouse model of ROP<sup>14–17</sup>. The present study found no differences regarding the total erythrocyte levels of n-3 PUFAs between the ROP and the no-ROP groups, probably because of high inter-individual differences. The principal component analysis revealed a differential clustering of the n-6 PUFA to n-3 PUFA ratio with GA in ROP group, suggesting that GA is an important variable to consider when evaluating the levels of n-6 and n-3 PUFAs in preterm infants. We also observed that GA is positively associated with the n-6 PUFA to n-3 PUFA ratio in infants who will develop ROP, which can be the sign of a possible remodeling of the n-6 to n-3 balance in favor of n-6 PUFA series. Interestingly, and when regarding individual n-6 and n-3 PUFAs, only the AA to DHA ratio revealed a time-dependent accumulation of AA at the expense of DHA in erythrocytes in the ROP group. Since AA and DHA are precursors of metabolically active molecules involved in inflammation<sup>39</sup>, such a differential age-dependent evolution of the AA to DHA ratio can have consequences on the inflammatory status of infants, which is a known additional risk factor of ROP<sup>40,41</sup>. Moreover, n-3 PUFAs are involved in retinal vascularization by limiting the development of avascular areas and neovascularization processes at the early and late phases of the disease, respectively<sup>14,34,35</sup>. In these animal studies, n-6 PUFAs were not shown to be protective against the development of ROP.

Numerous human studies suggest that PUFAs from the n-3 series reduce the likelihood of premature birth<sup>12,13</sup>. Particularly, EPA and its oxygenated derivative Resolvin E3 have been shown to lower preterm delivery in mice<sup>42</sup>. A recent study on African Americans showed that a higher maternal erythrocyte membrane AA to DHA ratio was associated to an increased risk of preterm birth<sup>43</sup>. In a Japanese population, the length of gestational period positively correlated with DHA concentrations in maternal erythrocyte membranes<sup>44</sup>. DHA levels in erythrocytes was shown to range between 5.5 and 5.8% of total fatty acids in mothers who delivered nearly full-term and full
<figure><img src="image_10.png" /><figcaption>**Figure 4.** Erythrocyte membrane concentrations of selected PUFAs from n-6 and n-3 series in mothers of infants with or without ROP. Results are presented as median and interquartile range. ROP: retinopathy of prematurity; AA: arachidonic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; NS: non significant; FAMEs: fatty acid methyl esters; DMAs: dimethylacetals.</figcaption></figure>

term infants (38 to 40 weeks GA)44,45, and was shown to be reduced to until 2.5% of total fatty acids in mothers of 33 weeks-GA preterm infants43. Although they have to be confirmed at a larger scale, the data we obtained on mothers confirm these findings as we measured DHA at a level of 3.8% of total fatty acids in erythrocytes of mothers of preterm infants of less than 29 weeks GA. These findings reinforce the idea of supplementing mothers with n-3 PUFAs in order to reach blood levels consistent with an increased likelihood of delivering a full-term child. As one of the best way to reduce the incidence of ROP is to have a full-term delivery, it would consist in using the mother as a source of increased n-3 fatty acid delivery to the developing fetus.

Contrary to our data on infant erythrocyte membrane fatty acid composition, data obtained by Löfqvist and collaborators show that a reduced area under the curve of AA during the 1st month of life is associated with a higher risk of ROP26. These findings are somewhat unexpected regarding the numerous and consistent experimental data on the properties of n-6 and n-3 PUFAs. They are likely to be the consequence of the dietary supply of the newborns and underline the difficulty of drawing a reliable picture of blood fatty acid status in newborns over the 1st weeks and months of life.

In the present study, we can hypothesize that the differences observed between subjects who will suffer or not suffer from ROP might be the result of differential *in utero* bioavailability of n-6 and n-3 PUFAs. Indeed, it was shown that the AA and DHA balance of the fetus is regulated through the placental transfer of fatty acids from the mother46. Other findings have shown that whereas the AA to DHA ratio is initially high in the fetus, the maternal transfer of DHA increases during the last trimester of gestation, resulting in a lower AA to DHA ratio at term47.
Our data are concordant with abnormalities in placental PUFA transfer in preterm infants who will develop ROP. In this study, we could also analyze erythrocyte fatty acids on a reduced number of mothers. These preliminary data seem to sustain such a hypothesis since they highlight differences in red blood cell concentrations of DHA between mothers of infants that will develop or not ROP. Particularly, we have found DHA levels in maternal erythrocytes to be of about 4.9% of total fatty acids, which appears to be high considering the length of gestation as shown by others and as discussed above⁴³⁻⁴⁵. Such a finding can be the consequence of DHA accumulation in mothers of infants who will develop ROP and can explain why the AA to DHA ratio in infants with ROP is increased with higher GA. However, these analyses have to be repeated on a larger number of mothers to confirm this hypothesis. Moreover, mechanistic studies are needed to determine whether defects in placental transfer of n-3 PUFAs are involved in the modifications in maternal and fetal erythrocyte fatty acids observed in the ROP group.

We acknowledge several limitations to our study. First, the number of subjects is low. Second, the population includes only three ROP cases that required treatment, whereas such cases are the most concerned by neovascular abnormalities.

In conclusion, this study shows that erythrocyte lipids of preterm infants who will develop or not develop ROP display different patterns in terms of n-6 and n-3 PUFA compositions. Since erythrocyte membranes are a good mirror of retinal lipid composition in the newborn⁴⁸⁻⁵⁰, these data raise the question of potential modifications of retinal lipid metabolism in ROP with potential links with inflammatory and angiogenic processes.

## Materials and Methods

**Ethics statement.** Samples were collected in accordance with the guidelines of the Declaration of Helsinki. The experimental protocol was approved by local ethics committee (CPP Est III, School of Medicine, Dijon, France) that waived the need to obtain written consent. However, an information note was given to parents and/or legal guardians. In accordance with “ethical considerations for clinical trials on medicinal products conducted with the paediatric population”, the volume of blood collected was limited to 0.5 mL⁵¹.

**Selection of the patients.** From July 31st, 2015, to January 31st, 2018, all preterm infants born before 29 weeks GA and hospitalized in the neonatal intensive care unit of the Dijon University Hospital, Dijon, France, were included in the study. A 0.5-mL blood sample was collected by venipuncture within the first 48 h of life in a heparinized tube. A 5-mL blood sample was also taken from a reduced number of mothers within a maximum delay of 5 days following child delivery. Red blood cells were immediately separated from serum and samples were stored at -80°C until lipidomic analyses.

ROP screening was performed with the wide-field RETCAM II® camera (Clarity Medical Systems; Pleasanton, CA, USA) using a lid speculum after topical anesthesia by chlorhydrate oxybuprofacin (1.6 mg/0.4 mL). Pupillary dilation was previously performed using one drop of 2.5% epinephrine (Phenylephrine 5% diluted to 2.5%) and one drop of tropicamide (2 mg/0.4 mL). The procedure was completed by a trained nurse and all fundus photographs were analyzed by a trained pediatrics-specialized ophthalmologist. Screening began at 4-6 weeks of life but never before 31 weeks of postconceptional age (PCA), and was repeated every other week until 39 weeks PCA if no ROP was detected, and every week and up to twice a week in case of ROP. ROP staging was determined according to the International Classification of ROP⁵². Patients were classified in the group suffering from ROP (ROP group) or in the group of unaffected controls (no-ROP group). Within the ROP group, subjects were classified into ROP type 1 and ROP type 2. The major risks of developing ROP, namely term and weight at birth, duration of mechanical ventilation, sepsis, use of erythropoietin, red blood cell transfusion and cerebral hemorrhage were documented.

**Lipidomic analyses.** The red blood cell fatty acid composition was determined according to previously described procedures⁵³⁻⁵⁵. Briefly, total lipids were extracted from erythrocytes according to Moilanen and Nikkari⁵⁶. Phospholipids were purified from total lipid extracts using silica cartridges⁵⁷, and transmethylated using boron trifluoride in methanol⁵⁸. The fatty acid methyl esters (FAMEs) and dimethylacetals (DMAs) formed were analyzed on a Hewlett Packard Model 5890 gas chromatograph as previously described⁵³⁻⁵⁵. The data were processed using the EZChrom Elite software (Agilent Technologies, Massy, France) and reported as a percentage of the total FAMEs and DMAs.

**Statistical analysis.** Statistical analysis was performed using GraphPad Prism v6.05 (GraphPad Software, San Diego, CA, USA) and XLSTAT v2018.02.50494 (Addinsoft, Paris, France). Quantitative data are expressed as median and interquartile range [IQR]. The groups were compared using the nonparametric Mann-Whitney test for quantitative variables and the Chi-2 test or Fisher exact test for qualitative variables. A principal component analysis and Spearman correlations were used to analyze the extent to which the fatty acid composition of erythrocytes was associated with the major risk factors of ROP, namely mechanical ventilation, birthweight and GA. Linear regression analyses were carried out to compare the levels of individual or total n-3 and n-6 PUFAs or n-3 and n-6 PUFAs ratios as a function of GA. A p-value lower than 0.05 was considered as statistically significant and the tests were two-tailed.

## References

1. Terry, T. L. Fibroblastic Overgrowth of Persistent Tunica Vasculosa Lentis in Infants Born Prematurely: II. Report of Cases-Clinical Aspects. *Trans Am Ophthalmol Soc* 40, 262–284 (1942).

2. Steinkuller, P. G. et al. Childhood blindness. *J AAPOS* 3, 26–32 (1999).

3. Good, W. V. & Hardy, R. J. The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP). *Ophthalmology* 108, 1013–1014 (2001).
4. Jordan, C. O. Retinopathy of prematurity. *Pediatr Clin North Am* **61**, 567–577, https://doi.org/10.1016/j.pcl.2014.03.003 (2014).

5. Karkhaneh, R. et al. Incidence and risk factors of retinopathy of prematurity in a tertiary eye hospital in Tehran. *Br J Ophthalmol* **92**, 1446–1449, https://doi.org/10.1136/bjo.2008.145136 (2008).

6. Lad, E. M., Hernandez-Boussard, T., Morton, J. M. & Moshfeghi, D. M. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. *Am J Ophthalmol* **148**, 451–458, https://doi.org/10.1016/j.ajo.2009.04.018 (2009).

7. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. *Pediatrics* **105**, 295–310 (2000).

8. Fortes Filho, J. B., Eckert, G. U., Procianoy, L., Barros, C. K. & Procianoy, R. S. Incidence and risk factors for retinopathy of prematurity in very low and in extremely low birth weight infants in a unit-based approach in southern Brazil. *Eye (Lond)* **23**, 25–30, https://doi.org/10.1038/sj眼.6702924 (2009).

9. Romagnoli, C., Tesfagabir, M. G., Giannantonio, C. & Papacci, P. Erythropoietin and retinopathy of prematurity. *Early Hum Dev* **87**(Suppl 1), S39–42, https://doi.org/10.1016/j.earlhumdev.2011.01.027 (2011).

10. Mohamed, S., Murray, J. C., Dagle, J. M. & Colaizy, T. Hyperglycemia as a risk factor for the development of retinopathy of prematurity. *BMC Pediatr* **13**, 78, https://doi.org/10.1186/1471-2431-13-78 (2013).

11. Jalali, S., Madhavi, C., Reddy, G. P. & Nutheti, R. Pilot study on *in vivo* evaluation of retinal vascular maturity in newborn infants in the context of retinopathy of prematurity. *Am J Ophthalmol* **142**, 181–183, https://doi.org/10.1016/j.ajo.2006.02.017 (2006).

12. Kar, S., Wong, M., Rogozinska, E. & Thangaratinam, S. Effects of omega-3 fatty acids in prevention of early preterm delivery: a systematic review and meta-analysis of randomized studies. *Eur J Obstet Gynecol Reprod Biol* **198**, 40–46, https://doi.org/10.1016/j. ejogr.2015.11.033 (2016).

13. Makrides, M. & Best, K. Docosahexaenoic Acid and Preterm Birth. *Ann Nutr Metab* **69**(Suppl 1), 29–34, https://doi.org/10.1159/000448263 (2016).

14. Connor, K. M. et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. *Nat Med* **13**, 868–873 (2007).

15. Leduc, M., Kermorvant-Duchemin, E., Checchin, D., Sennlaub, F. & Chemtob, S. Hypercapnia- and trans-arachidonic acid-induced retinal microvascular degeneration: implications in the genesis of retinopathy of prematurity. *Med Sci (Paris)* **23**, 939–943, https://doi.org/10.1051/medsci/20072311939 (2007).

16. Leduc, M. et al. Hypercapnia- and trans-arachidonic acid-induced retinal microvascular degeneration: implications in the genesis of retinopathy of prematurity. *Semin Perinatol* **30**, 129–138, https://doi.org/10.1053/j.semperi.2006.04.004 (2006).

17. Stahl, A. et al. Lipid metabolites in the pathogenesis and treatment of neovascular eye disease. *Br J Ophthalmol* **95**, 1496–1501, https://doi.org/10.1136/bjo.2010.194241 (2011).

18. Abribat, T., Nedelec, B., Jobin, N. & Garrel, D. R. Decreased serum insulin-like growth factor-I in burn patients: relationship with serum insulin-like growth factor binding protein-3 proteolysis and the influence of lipid composition in nutritional support. *Crit Care Med* **28**, 2366–2372 (2000).

19. Calviello, G. et al. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. *Carcinogenesis* **25**, 2303–2310 (2004).

20. Szymczak, M., Murray, M. & Petrovic, N. Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases. *Blood* **111**, 3514–3521, https://doi.org/10.1182/blood-2007-08-109934 (2008).

21. Smith, L. E. et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. *Nat Med* **5**, 1390–1395, https://doi.org/10.1038/70963 (1999).

22. Hellstrom, A. et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. *Proc Natl Acad Sci USA* **98**, 5804–5808, https://doi.org/10.1073/pnas.101113998 (2001).

23. Smith, L. E. Pathogenesis of retinopathy of prematurity. *Growth Horm IGF Res* **14**(Suppl A), S140–144, https://doi.org/10.1016/j.ghir.2004.03.030 (2004).

24. Smith, L. E. IGF-I and retinopathy of prematurity in the preterm infant. *Biol Neonate* **88**, 237–244, https://doi.org/10.1159/000087587 (2005).

25. Martin, C. R. et al. Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. *J Pediatr* **159**(743–749), e741–742, https://doi.org/10.1016/j.jpeds.2011.04.039 (2011).

26. Lofqvist, C. A. et al. Association of Retinopathy of Prematurity With Low Levels of Arachidonic Acid: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Ophthalmol* **136**, 271–277, https://doi.org/10.1001/jamaophthalmol.2017.6658 (2018).

27. Allvin, K., Hellstrom, A., Dahlgren, J. & Andersson Gronlund, M. Birth weight is the most important predictor of abnormal retinal vascularisation in moderately preterm infants. *Acta Paediatr* **103**, 594–600, https://doi.org/10.1111/apa.12599 (2014).

28. Hellstrom, A., Smith, L. E. & Dammann, O. Retinopathy of prematurity. *Lancet* **382**, 1445–1457, https://doi.org/10.1016/S0140-6736(13)60178-6 (2013).

29. Austeng, D., Kallen, K. B., Ewald, U. W., Jakobsson, P. G. & Holmstrom, G. E. Incidence of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. *Arch Ophthalmol* **127**, 1315–1319, https://doi.org/10.1001/archophthalmol.2009.244 (2009).

30. Yuan, L. et al. The Erythrocyte Fatty Acid Profile and Cognitive Function in Old Chinese Adults. *Nutrients* **8**, https://doi.org/10.3390/nu8070385 (2016).

31. Pearson, H. A. Life-span of the fetal red blood cell. *J Pediatr* **70**, 166–171 (1967).

32. Collins, C. T. et al. A dose response randomised controlled trial of docosahexaenoic acid (DHA) in preterm infants. *Prostaglandins Leukot Essent Fatty Acids* **99**, 1–6, https://doi.org/10.1016/j.plefa.2015.04.003 (2015).

33. Smithers, L. G., Gibson, R. A., McPhee, A. & Makrides, M. Effect of two doses of docosahexaenoic acid (DHA) in the diet of preterm infants on infant fatty acid status: results from the DINO trial. *Prostaglandins Leukot Essent Fatty Acids* **79**, 141–146, https://doi.org/10.1016/j.plefa.2008.09.015 (2008).

34. Sapieha, P. et al. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. *Sci Transl Med* **3**, 69ra12, https://doi.org/10.1126/scitranslmed.3001571 (2011).

35. Stahl, A. et al. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. *Circ Res* **107**, 495–500, https://doi.org/10.1161/CIRCRESAHA.110.221317 (2010).

36. Augood, C. et al. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. *Am J Clin Nutr* **88**, 398–406 (2008).

37. Chua, B. et al. Dietary fatty acids and the 5-year incidence of age-related maculopathy. *Arch Ophthalmol* **124**, 981–986 (2006).

38. Tikhonenko, M. et al. N-3 polyunsaturated Fatty acids prevent diabetic retinopathy by inhibition of retinal vascular damage and enhanced endothelial progenitor cell reparative function. *PLoS ONE* **8**, e55177, https://doi.org/10.1371/journal.pone.0055177 (2013).

39. Calder, P. C. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. *Biochim Biophys Acta* **1851**, 469–484, https://doi.org/10.1016/j.bbalip.2014.08.010 (2015).

40. Hong, H. K. et al. Neonatal systemic inflammation in rats alters retinal vessel development and simulates pathologic features of retinopathy of prematurity. *J Neuroinflammation* **11**, 87, https://doi.org/10.1186/1742-2094-11-87 (2014).

41. Hartnett, M. E. Pathophysiology and mechanisms of severe retinopathy of prematurity. *Ophthalmology* **122**, 200–210, https://doi.org/10.1016/j.ophtha.2014.07.050 (2015).

42. Yamashita, A. et al. Increased tissue levels of omega-3 polyunsaturated fatty acids prevents pathological preterm birth. *Sci Rep* **3**, 3113, https://doi.org/10.1038/srep03113 (2013).
43. Christian, L. M. et al. Polyunsaturated Fatty Acid (PUFA) Status in Pregnant Women: Associations with Sleep Quality, Inflammation, and Length of Gestation. *PLoS One* 11, e0148752, https://doi.org/10.1371/journal.pone.0148752 (2016).

44. Kitamura, Y. et al. Fatty Acid Composition of the Erythrocyte Membranes Varies between Early-Term, Full-Term, and Late-Term Infants in Japan. *Ann Nutr Metab* 73, 335-343, https://doi.org/10.1159/000494886 (2018).

45. Assumpcao, R. P. et al. Fatty acid profile of maternal and fetal erythrocytes and placental expression of fatty acid transport proteins in normal and intrauterine growth restriction pregnancies. *Prostaglandins Leukot Essent Fatty Acids* 125, 24-31, https://doi.org/10.1016/j.plefa.2017.08.011 (2017).

46. Kuipers, R. S. et al. Maternal DHA equilibrium during pregnancy and lactation is reached at an erythrocyte DHA content of 8 g/100 g fatty acids. *J Nutr* 141, 418-427, https://doi.org/10.3945/jn.110.128488 (2011).

47. Bernhard, W. et al. Developmental changes in polyunsaturated fetal plasma phospholipids and feto-maternal plasma phospholipid ratios and their association with bronchopulmonary dysplasia. *Eur J Nutr* 55, 2265-2274, https://doi.org/10.1007/s00394-015-1036-5 (2016).

48. Carlson, S. E., Carver, J. D. & House, S. G. High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: a comparison of rat neural and red cell membrane phospholipids. *J Nutr* 116, 718-725 (1986).

49. Makrides, M., Neumann, M. A., Byard, R. W., Simmer, K. & Gibson, R. A. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. *Am J Clin Nutr* 60, 189-194 (1994).

50. Sarkadi-Nagy, E. et al. Formula feeding potentiates docosahexaenoic and arachidonic acid biosynthesis in term and preterm baboon neonates. *J Lipid Res* 45, 71-80 (2004).

51. European Union. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. *Eur J Health Law* 15, 223-250 (2008).

52. International Committee for the Classification of Retinopathy of the Eye. The International Classification of Retinopathy of Prematurity revisited. *Arch Ophthalmol* 123, 991-999, https://doi.org/10.1001/archopth.123.7.991 (2005).

53. Ajana, S. et al. Benefits of dimension reduction in penalized regression methods for high dimensional grouped data: a case study in low sample size. *Bioinformatics*, submitted (2018).

54. Acar, N. et al. Red blood cell plasmalogens and docosahexaenoic acid are independently reduced in primary open-angle glaucoma. *Exp Eye Res* 89, 840-853 (2009).

55. Koehrer, P. et al. Erythrocyte Phospholipid and Polyunsaturated Fatty Acid Composition in Diabetic Retinopathy. *PLoS ONE* 9, e106912, https://doi.org/10.1371/journal.pone.0106912 (2014).

56. Moilanen, T. & Nikkari, T. The effect of storage on the fatty acid composition of human serum. *Clin Chim Acta* 114, 111-116 (1981).

57. Juaneda, P. & Rocquelín, G. Rapid and convenient separation of phospholipids and non phosphorus lipids from rat heart using silica cartridges. *Lipids* 20, 40-41 (1985).

58. Morrison, W. R. & Smith, L. M. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride methanol. *J Lipid Res* 53, 600-608 (1964).

## Acknowledgements

The authors would like to thank the VISIO Foundation for its support. This work has been funded by the Regional Council of Burgundy France (PARI Agral 1), FEDER (European Funding for Regional Economical Development), Association Nationale Recherche Technologie, Fondation de France/Fondation de l'Oeil, Agence Nationale de la Recherche [ANR-11-LABEX-0021].

## Author Contributions

C.P., C.M., D.S.S., C.P.C.-G., L.B., N.A. designed the study. C.P., J.M., D.S.S., C.C., N.T., D.M., A.D., S.G., N.A. acquired, analyzed and interpreted the data. C.P., J.M., D.S.S., A.M.B., C.P.C.-G., L.B., N.A. drafted the manuscript. All authors reviewed the manuscript.

## Additional Information

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_11.png" /></figure>

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019